February 05, 2018 – Strainprint was featured in the Daily Marijuana Observer which discusses 5 of the Most Common Ailments Being Treated with Medical Marijuana
TORONTO, Dec. 21, 2017 /CNW/ – Strainprint™ – the leader in cannabis data collection and strain efficacy reporting – is excited to announce that 48North Cannabis (48North) has subscribed to Strainprint’s world-leading cannabis data & analytics platform to help guide its operational growth and product development.
48North’s Ontario-based cultivation facility Delshen Therapeutics is a Health Canada Licensed Producer with unique genetics sourced from the Netherlands’ first cannabis license holder, MariPharm B.V. 48 North plans to use Strainprint’s data and analytics tools to support the existing medical research on their proprietary strains and to develop cannabis products and brands that meet the needs of a variety of consumers.
“Strainprint’s unique ACMPR strain efficacy and patient use data will help us to produce the highest quality products that will support our patients and recreational consumers in navigating their cannabis experiences.,” said Alison Gordon, 48North CEO.
Thousands of ACMPR patients have tracked almost 150,000 medication sessions from our industry-leading mobile app generating over 4 million data points on strain efficacy and patient use. It is the largest and most granular longitudinal data set in the world on strain efficacy and patient use of lab-verified products. In addition to guiding patients, this data is helping to shape the entire cannabis industry by providing business intelligence for all stakeholders, including licensed producers, doctors and clinics, researchers, pharma and insurance providers.
“Our mission is to help our users and our subscriber customers to better understand how cannabis works and how it can best be used for whatever their purpose. We are ecstatic to be working with 48North to provide them with the most reliable source of data that will be instrumental for developing premium products for their consumers and patients,” said Strainprint CEO, Andrew Muroff.
The Strainprint mobile App is free and is available for both iOS & Android from the Apple iTunes and Google Play Stores, respectively.
Founded in Toronto in 2016, Strainprint™ Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. Strainprint™ data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. For more information visit www.strainprint.ca, facebook, twitter, linkedin
About 48 North
48North is a vertically integrated cannabis company. Its first ACMPR licensed facility is located on 800 acres of owned land near Kirkland Lake, Ontario, and is operated by its wholly-owned subsidiary, DelShen Therapeutics. The company grows unique genetics sourced from MariPharm B.V., a Netherlands based phytopharmaceutical company with over 25 years of experience in the research and cultivation of cannabis for medical purposes. The genetics are grown to exacting standards in DelShen’s state-of-the-art, closed box facility, ensuring patients can count on receiving the highest quality cannabis products. 48North’s values are rooted in the land they’re planted on, and the company has entered into a first of its kind Community Benefits Agreement with certain of its First Nations investors.
SOURCE Strainprint™ Technologies Ltd.
Strainprint Technologies Ltd.
Strainprint Founder, Stephanie Karasick was recently featured as a Cannabis Influencer in the Marijuana Retail Report:
As the Strainprint community grows, we have the pleasure of meeting different people from across the country who rely on the app daily for their medical marijuana dosing and information.
Last Patient Profile, we featured the story of Jennifer Raymond, who suffers from psoriatic arthritis who found that cannabis was the key to helping her manage her regular pain while maintaining a high-degree of function as a busy working mother.
This month, we’re pleased to feature the story of Mike Rudichuk, who was generous enough to share his journey with cannabis and Strainprint with our team.
Mike became a medical cannabis patient 2 years ago as a result of chronic and debilitating pain due to herniated disks in his lower back that were impacting his daily life. As a young father of just 36 who has a full-time job, hobbies, and a household to run, Mike needed something to help take the edge off from the back pain that was impacting every aspect of his life. Like many other Canadians, he turned to opioid painkillers to help manage his pain.
He found that his body was becoming highly tolerant of the pain medications, requiring an increase in his doses regularly. His pain wasn’t being managed as much as just masked, and he was feeling that the strong chemicals in the pharmaceuticals were taking a negative toll on his overall health. The side effects he experienced didn’t seem worth the struggle. Concerned about this, when found that if he tried to lower his doses, or even take time away from the prescriptions, he’d experience withdrawal. He began to be concerned about his long-term health and how his body would be able to manage going off the opioids entirely. It was time to look for an alternative.
Through open dialogue with his own Family Doctor, Mike decided to try medical cannabis as an alternative to the strong opioids he was using. Luckily, his doctor even committed to walking this journey with him so that he could understand how medical cannabis would make a difference in his pain management.
Within a few months, Mike found that he had made more progress managing his pain using certain cannabis strains than he ever had over years of using pain pills. Mike prefers to use low-THC high-CBD strains like Zen’s Garden from Emblem.
He vapes, usually in the mornings and afternoons to help get through the days. The lower THC in small doses helps him attack his pain without a loss of clarity, whereas he felt like he was in “outer space” with opioid use.
When asked about his journey in pain management, Mike says, “If there is one thing I could change, it would have been to start using medical cannabis sooner.”
Mike & Strainprint
Mike was an early user of Strainprint and recalls a time where customer service exceeded his expectations. After sending a Tweet to Strainprint making some suggestions about the app, he was connected with Strainprint’s CEO, David Berg, where there was an acknowledgment of feedback and an intentional effort to address upcoming software updates for the continuous improvement of the app. “Anytime a CEO takes time to personally respond to clients, you know you’re in the right place,” Mike says about his experience, “The wonderful people at Strainprint are patients like us, so they take feedback very seriously.”
Mike finds that tracking his daily regime helps him greatly to feel in control of his pain management, which is incredibly big deal to someone who has come off opiods.
Mike has the following advice for those interested to try medical cannabis for the first time:
“Don’t be afraid to talk to your doctor. It’s your body and your life, and you should be well aware of all treatment options including cannabis. I can use cannabis at any point of the day and not impair me to the point of not being able to function, whereas there were times with pain medications where I was so zoned out and not able to function properly. I’ve been given a better quality of life and have felt much better in general health overall since being off opioid pain-killers and using medical cannabis.”